

Press Release

Abliva AB (publ), 556595-6538
29 July 2022 08:30:00 CEST - Lund,
Sweden



Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 146,547,924, as a result of a preferential rights issue announced by the Board of Directors on 1 June 2022.

Today, the last trading day of the month, there are a total of 1,056,299,165 shares and votes in Abliva AB.

This information is information that Abliva AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-07-29 08:30 CEST.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>
Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>
Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Amended number of shares and votes in Abliva AB \(publ\)](#)

Abliva AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.